Prelude Capital Management’s Blueprint Medicines BPMC Stock Holding History

Prelude Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-600	Closed	-$48K	–	1468
2019 Q4	$48K	Hold	600	–	–	﹤0.01%	1351
2019 Q3	$44K	Buy	+600	New	+$51.9K	﹤0.01%	1208
2018 Q1	–	Sell	-600	Closed	-$45K	–	1510
2017 Q4	$45K	Buy	+600	New	+$42.2K	﹤0.01%	956

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's BPMC Position: Q3 2025 in Review

Prelude Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 60,154 shares — an estimated $7.71M sold.

Prelude Capital Management first reported a position in BPMC in Q2 2017 and held it in 11 quarters. The position peaked at $7.71M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Prelude Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 60,154 Blueprint Medicines shares in Q3 2025, an estimated $7.71M.
Prelude Capital Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 11 quarters.
Prelude Capital Management's Blueprint Medicines position peaked at $7.71M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.